Biotech Values

[jaybird249]

RXII ($1.38) has traded at a huge discount to fair value because it has been under the radar, but not for long. Recent articles in Barrons and Seeking Alpha have have identified RXII as a biotech laggard with huge potential.
RXII'S NEUVAX CANCER VACCINE RESULTS ARE UNPRECEDENTED.

BASED ON 3 YEARS OF DATA, THE VACCINE REDUCED THE BREAST CANCER RECURRANCE RATE FROM 22% TO 0%.
http://finance.yahoo.com/news/RXi-Pharma...

THE RXII VACCINE IS MORE EFFECTIVE THAN DNDN PROVENGE.
DNDN HAS A $5.6 BILLION MARKET CAP.

The vaccine was so effective in Phase 2 that the FDA granted a Special Protocol Assessment for Phase 3.

RXII has $25 MM cash and a $55 MM market cap, meaning the market is valuing its technology at $30 million. The current market cap does not reflect the $5 billion market potential of RXII's Neuvax cancer vaccine.

The potential market for a breast cancer vaccine is staggering. Only 25% of all breast cancer patients, those with HER2 3+ disease are eligible for Herceptin which had 2010 revenues of over $5 billion. NeuVax targets the remaining 50% of HER2 positive patients.

RXII trades at a huge discount to other cancer vaccine stocks with no proven effacacy. In 2007 GNVC rose to a a $250 million market cap based on a cancer vaccine prospect. AGEN currently has a $100 million market cap.

Roth Capital has a $4 target for RXII, which would reflect a $120 million market cap. The most successful US Hedge Funds, Renaissance Technologies and Blackrock, hold RXII.